BioLife Solutions Announces CFO Retirement

Rhea-AI Summary

BioLife Solutions (Nasdaq: BLFS) announced the retirement of CFO Roderick de Greef, effective December 31, 2021. He will assist in the transition until March 31, 2022. De Greef has been vital to the company for over 20 years, significantly impacting its growth and funding strategies. The company has engaged executive search firm Strawn Arnold to find his successor. CEO Mike Rice expressed gratitude for de Greef's contributions, emphasizing his instrumental role during a period of significant expansion.

Positive

• Roderick de Greef served over 20 years, contributing to significant growth and funding.
• The company is actively searching for a successor, ensuring continuity.

Negative

• None.

BOTHELL, Wash., Sept. 15, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that Roderick de Greef, Chief Financial Officer, plans to retire on December 31, 2021 after a distinguished career with the Company. The Company has retained executive search firm Strawn Arnold to identify candidates to succeed Mr. de Greef.  Mr. de Greef will consult with the Company through March 31, 2022, to ensure an orderly transition of his duties.

Mike Rice, BioLife CEO, commented, "The entire team, our board and shareholders are extremely grateful to Rod for his 20+ years of contributing to the success of BioLife.  He was instrumental in securing funding in the early years and during his long tenure first as a board member and later as CFO, Rod has had an immeasurable positive impact as we scaled the business organically and though our acquisitions over the past two years. We will miss him but wish him the best in a well-deserved retirement."

De Greef added, "It has been a real honor to be a part of the team that has built BioLife to what it is today. The last five years as CFO have been particularly rewarding and a great capstone to a career spanning forty years. In the future, I look forward to watching the company continue to grow and thrive."

About BioLife Solutions

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services. Our portfolio includes our proprietary CryoStor^® freeze media and HypoThermosol^® shipping and storage media, ThawSTAR^® family of automated, water-free thawing products, evo^® cold chain management system, Custom Biogenic Systems^® high-capacity cryogenic freezers, Stirling Ultracold ULT freezers, and SciSafe biologic materials storage. For more information, please visit www.biolifesolutions.com, www.scisafe.com, www.stirlingultracold.com, www.sextonbio.com and follow BioLife on Twitter.

Contacts:

At the Company
Roderick de Greef
Chief Financial Officer
(425) 686-6002
rdegreef@biolifesolutions.com

Investors
LHA Investor Relations
Jody Cain
(310) 691-7100
jcain@lhai.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-announces-cfo-retirement-301377282.html

SOURCE BioLife Solutions, Inc.

FAQ

Who is retiring from BioLife Solutions?

Roderick de Greef, the Chief Financial Officer.

When is Roderick de Greef's retirement date?

His retirement is set for December 31, 2021.

How long will Roderick de Greef assist BioLife Solutions after retirement?

He will consult until March 31, 2022.

Who will identify a new CFO for BioLife Solutions?

The company has retained the executive search firm Strawn Arnold to find a successor.

What role did Roderick de Greef play at BioLife Solutions?

He was instrumental in securing funding and scaling the business.